Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30241191 | 1.00 | KDM4E (0.50) | KDM4EHTTALDH1A1GAAPIM1 | |
| SCHEMBL27583246 | 0.98 | KDM4E (0.49) | KDM4EHTTALDH1A1GAAPIM1 | |
| SCHEMBL7374228 | 0.84 | CDC25B (0.48) | HTTPRKCZKMT2ATDP1NR4A1 | |
| SCHEMBL2149297 | 0.82 | NR4A1 (0.59) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL30430793 | 0.82 | NR4A1 (0.59) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| Bromide SCHEMBL7369447 | 0.82 | CDC25B (0.47) | HTTPRKCZKMT2ATDP1NR4A1 | |
| SCHEMBL6627806 | 0.81 | PRKCZ (0.43) | KDM4EHTTALDH1A1PRKCZKMT2A | |
| SCHEMBL22389411 | 0.81 | PRKCZ (0.43) | KDM4EHTTALDH1A1PRKCZKMT2A | |
| Hydrochloric Acid SCHEMBL4617820 | 0.81 | NR4A1 (0.57) | KDM4EALDH1A1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL8966381 | 0.81 | CYP11B1 (0.43) | KDM4EALDH1A1PRKCZKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013005168-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | claimed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| EP-2069325-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | Serenex, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008024977-A2 | ISOQUINOLINE, QUINAZOLINE AND PHTHALAZINE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-12509439-B2 | Anti-malarial agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | disclosed |
| CN-115380027-B | Novel antimalarial agents | 肯塔基大学研究基金会 | 2024-10-18 | — | — | CN | disclosed |
| EP-4249480-A1 | DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Northwest A&F University (CN) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023145804-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2023-08-03 | — | — | WO | disclosed |
| US-20230174503-A1 | NEW ANTI-MALARIAL AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2023-06-08 | — | — | US | disclosed |
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| EP-4132918-A1 | NEW ANTI-MALARIAL AGENTS | University Of Kentucky Research Foundation (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115380027-A | Novel antimalarial agents | 肯塔基大学研究基金会 | 2022-11-22 | — | — | CN | disclosed |
| EP-0191788-A1 | NOVEL RADIOPHARMACEUTICALS AND CHELATING AGENTS USEFUL IN THEIR PREPARATION | UNIVERSITY OF FLORIDA (US) | 1986-08-27 | — | — | EP | disclosed |
| EP-0187832-A1 | COMPOUNDS FOR SITE-ENHANCED DELIVERY OF RADIONUCLIDES AND USES THEREOF | UNIVERSITY OF FLORIDA (US) | 1986-07-23 | — | — | EP | disclosed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | disclosed |
| WO-1986000897-A1 | NOVEL RADIOPHARMACEUTICALS AND CHELATING AGENTS USEFUL IN THEIR PREPARATION | UNIVERSITY OF FLORIDA (US) | 1986-02-13 | — | — | WO | disclosed |
| WO-1986000898-A1 | COMPOUNDS FOR SITE-ENHANCED DELIVERY OF RADIONUCLIDES AND USES THEREOF | UNIVERSITY OF FLORIDA (US) | 1986-02-13 | — | — | WO | disclosed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | disclosed |
| US-4396619-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382932-A | Isoquinolinium substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108442-A1 | NOVEL ANTIMALARIAL AGENT CONTAINING HETEROCYCLIC COMPOUND | QDPR, DHODH, THPO | KDM4E 2242/4885HTT 2670/4885ALDH1A1 1785/4885 |
| US-12509439-B2 | Anti-malarial agents | RCC1, PFN1, NHERF1 | KDM4E 3704/4885HTT 1660/4885ALDH1A1 1353/4885 |
| US-20230174503-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHODH, G6PD | KDM4E 1107/4885HTT 3183/4885ALDH1A1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.